EFTR Stock — Effector Therapeutics Inc

Effector Therapeutics Inc (EFTR)

Updated October 14, 2026.

EFTR is a Stock. Total return is -100.0% over the past 5.6 years, 213.3 points behind SPY at 113.3%.

Effector Therapeutics is a biopharmaceutical company developing selective translation regulator inhibitors for cancer treatment. Its lead candidate, Zotatifin, is an eIF4A inhibitor in Phase 1/2 trials for solid tumors and has completed Phase 2 testing in combination therapy for ER+ breast cancer, while a second program, Tomivosertib, is in Phase 2b development for metastatic non-small cell lung cancer; the company also partners with Pfizer on related research. The company does not currently distribute dividends and is characteristic of early-stage biotech firms focused on clinical development rather than generating shareholder income.

EFTR performance versus SPY

Price and return data through 2026-10-14.

Total return is -100.0% over the past 5.6 years, 213.3 points behind SPY at 113.3%. Over the past year its total return — price change plus distributions reinvested — is 0.0%. Its deepest 1-year drawdown was 75.0%.

EFTR key facts

Asset type

Stock

Asset class

Equity

Inception date

03/01/2021

Distribution frequency

None

Last close

$0.0002 (stale; as of 2026-10-14)

Market cap

$941

Average volume

0.0

Beta

2.737

Payout ratio

0.0%

EPS

$-12.78

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

EFTR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 75.0%.

Who may consider EFTR — and who may not

It is a weaker fit for investors who need monthly cash flow (EFTR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on EFTR

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions